21q4 all public funds accounted for 11.11%, with a month on month ratio of -2.16pp; Excluding active pharmaceutical funds, accounting for 7.33%, mom -2.02pp; Excluding index funds, the proportion accounted for 6.76%, with a month on month ratio of -2.57pp; The market value of Shenwan pharmaceutical sector accounted for 8.49%, with a month on month increase of + 0.24pp.
In terms of the number of public fund positions, the top five public funds are Wuxi Apptec Co.Ltd(603259) (655), Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) (515), Chongqing Zhifei Biological Products Co.Ltd(300122) (226), Asymchem Laboratories (Tianjin) Co.Ltd(002821) (221), Aier Eye Hospital Group Co.Ltd(300015) (181); In terms of changes, the top five stocks for the increase in the number of funds are: Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) (+ 44), Shandong Pharmaceutical Glass Co.Ltd(600529) (+ 44), Huadong Medicine Co.Ltd(000963) (+ 44), Dong-E-E-Jiao Co.Ltd(000423) (+ 43), Yixintang Pharmaceutical Group Co.Ltd(002727) (+ 33).
From the position proportion of public funds, 1) the top five positions in the proportion of circulating shares are: Porton Pharma Solutions Ltd(300363) (31.9%), Asymchem Laboratories (Tianjin) Co.Ltd(002821) (23.8%), Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) (21.8%), Qingdao Novelbeam Technology Co.Ltd(688677) (21%), Hangzhou Tigermed Consulting Co.Ltd(300347) (20.2%); 2) The top five share capital positions are: Porton Pharma Solutions Ltd(300363) (26.2%), Asymchem Laboratories (Tianjin) Co.Ltd(002821) (22.8%), Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) (21.7%), Wuxi Apptec Co.Ltd(603259) (18.2%) and Hangzhou Tigermed Consulting Co.Ltd(300347) (15.9%).
In terms of the total market value of public fund positions, the top five are: Wuxi Apptec Co.Ltd(603259) (63.91 billion yuan), Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) (51.04 billion yuan), Asymchem Laboratories (Tianjin) Co.Ltd(002821) (26.07 billion yuan), Aier Eye Hospital Group Co.Ltd(300015) (22.11 billion yuan), Hangzhou Tigermed Consulting Co.Ltd(300347) (17.76 billion yuan); In terms of changes, the top five increases in the market value of fund positions were Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) (+ 7.23 billion yuan), Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) (+ 6.85 billion yuan), Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) (+ 3.77 billion yuan), Imeik Technology Development Co.Ltd(300896) (+ 2.65 billion yuan) and Shandong Pharmaceutical Glass Co.Ltd(600529) (+ 2.63 billion yuan).
In 21q4, the total market value of pharmaceutical and biological sectors held by foreign investors accounted for 3.12%, down 0.35pp month on month. The total market value of holdings was 262.9 billion yuan, down – 15.1 billion yuan month on month.
Judging from the proportion of positions,
1) the top five positions of tradable shares are Guangzhou Kingmed Diagnostics Group Co.Ltd(603882) (17.3%), Hangzhou Tigermed Consulting Co.Ltd(300347) (16.2%), Amoy Diagnostics Co.Ltd(300685) (16%), Yifeng Pharmacy Chain Co.Ltd(603939) (15.9%), Pharmaron Beijing Co.Ltd(300759) (15.3%); The top five increases in the proportion of tradable shares are: Jiuzhitang Co.Ltd(000989) (+ 3.2%), Shandong Pharmaceutical Glass Co.Ltd(600529) (+ 3%), Qingdao Haier Biomedical Co.Ltd(688139) (+ 2.9%), Amoy Diagnostics Co.Ltd(300685) (+ 2.3%), Guangzhou Kingmed Diagnostics Group Co.Ltd(603882) (+ 1.9%);
2) the top five positions in total share capital are Guangzhou Kingmed Diagnostics Group Co.Ltd(603882) (17.2%), Yifeng Pharmacy Chain Co.Ltd(603939) (15.9%), Amoy Diagnostics Co.Ltd(300685) (15.8%), Shandong Pharmaceutical Glass Co.Ltd(600529) (13.6%) and Dian Diagnostics Group Co.Ltd(300244) (11.8%); The top five increases in the proportion of total equity positions are: Yixintang Pharmaceutical Group Co.Ltd(002727) (+ 1.1%), Shanghai Kehua Bio-Engineering Co.Ltd(002022) (+ 1%), Shanxi Zhendong Pharmaceutical Co.Ltd(300158) (+ 0.9%), Shanghai Junshi Biosciences Co.Ltd(688180) (+ 0.8%) and Jiangsu Yuyue Medical Equipment And Supply Co.Ltd(002223) (+ 0.8%).
3) from the market value of positions, the top five are Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) (41.8 billion yuan), Jiangsu Hengrui Medicine Co.Ltd(600276) (34.1 billion yuan), Wuxi Apptec Co.Ltd(603259) (22.1 billion yuan), Aier Eye Hospital Group Co.Ltd(300015) (14.7 billion yuan), Hangzhou Tigermed Consulting Co.Ltd(300347) (11.7 billion yuan); The top five increases in the market value of positions are: Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) (+ 2.2 billion yuan), Shandong Pharmaceutical Glass Co.Ltd(600529) (+ 1.7 billion yuan), Guangzhou Kingmed Diagnostics Group Co.Ltd(603882) (+ 1.6 billion yuan), Dong-E-E-Jiao Co.Ltd(000423) (+ 600 million yuan), Shanghai Junshi Biosciences Co.Ltd(688180) (+ 500 million yuan).
Risk tip: the position analysis of public funds is based on the summary of the detailed holdings of heavy positions in the quarterly report of wind2021q3 disclosed by open-end and closed-end public funds in the Fund database. There is a risk of sample error caused by the fact that some stocks are outside the top ten heavy positions.
